Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology|November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Blood|November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaThierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology|November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Blood|November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaThierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 19